Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory b cell responses

Journal of Rheumatology

Volumn 41, Issue 5, 2014, Pages 825-828

  Silverman, Gregg J ^a   Pelzek, Adam ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR BLOCKER; B7 ANTIGEN; CD20 ANTIBODY; CD27 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; RHEUMATOID FACTOR; RITUXIMAB; TABALUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; AUTOANTIBODY; IMMUNOGLOBULIN;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; EDITORIAL; HUMAN; IMMUNE DYSREGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MEMORY CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; DRUG EFFECTS; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULINS; IMMUNOLOGIC MEMORY; MALE;

EID: 84899728228     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140022     Document Type: Editorial

References (30)

1. Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94.
2. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunology 2013;14:34.
3. Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014;41:666-72.
4. Bar-Or A, Oliveira EM, Anderson DE, Krieger JI, Duddy M, O'Connor KC, et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol 2001;167:5669-77. (Pubitemid 33062757)
5. Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
6. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013;210:445-55.
7. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012;71:1815-9.
8. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7. (Pubitemid 24291979)
9. Kroeger DR, Rudulier CD, Bretscher PA. Antigen presenting B cells facilitate CD4 T cell cooperation resulting in enhanced generation of effector and memory CD4 T cells. PLoS One 2013;8:e77346.
10. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
11. Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 2009;21:205-10.
12. Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol 2013;173:8-17.
13. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75. (Pubitemid 351847509)
14. Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008;223:175-85. (Pubitemid 351986172)
15. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11:R131.
16. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. ArthritisRheum 2003;48:2146-54. (Pubitemid 36959194)
17. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009;11:R84.
18. Catalan D, Aravena O, Sabugo F, Wurmann P, Soto L, Kalergis AM, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. ArthritisRes Ther 2010;12:R68.
19. Menard L, Samuels J, Ng YS, Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis.Arthritis Rheum 2011;63:1237-45.
20. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180:688-92.
21. Muraguchi A, Nishimoto H, Kawamura N, Hori A, Kishimoto T. B cell-derived BCGF functions as autocrine growth factor(s) in normal and transformed B lymphocytes. J Immunol 1986;137:179-86. (Pubitemid 16100286)
22. Muhammad K, Roll P, Seibold T, Kleinert S, Einsele H, Dorner T,et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 2011;70:1507-10.
23. Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, DornerT, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum2011;63:1255-64.
24. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG.Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013;72:118-28.
25. Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunology Lett 2012;143:2-8.
26. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
27. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72.
28. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C,Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63:1793-803.
29. Genovese M, Silverman J, Emery P, Gupta R, Gill A, KomocsarWJ, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study [abstract]. Arthritis Rheum 2013;65 Suppl 10:S733.
30. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus:combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.